RadioMedix, Inc. is a clinical stage biotechnology company, based in Houston, Texas, focused on innovative targeted radiopharmaceuticals for diagnosis, monitoring, and therapy of cancer. The company is commercializing radiopharmaceuticals for PET imaging and therapeutic (alpha and beta-labeled) radiopharmaceuticals. RadioMedix has also established contract service facilities for academic and industrial partners: Full cGMP manufacturing and analytical suites for human clinical trials, and commercial phase manufacturing of the radiopharmaceuticals, in addition to small animal Molecular Imaging Center for the pre-clinical evaluation of new targets in vitro and in vivo.

From Bench To Bedside

RadioMedix offers a multitude of services. Our bench to bedside capabilities includes drug candidate selection, optimization of the drug formulation, evaluation of in vitro and in vivo studies in relevant disease models and a multitude of other preclinical services.



PRE CLINICAL

• Radiochemistry & Preclinical In Vitro Screening 

• In Vivo Toxicity, Efficacy, & Dosimetry in mice 

• Micro PET Imaging

CLINICAL & INVESTIGATIONAL

•Clinical trial designs & IND Filing 

• Alpha/Beta Emitter Radiolabeling

• On-Site Clinical Center



COMMERCIAL SCALE MANUFACTURING

•24,500 SQF Manufacturing & QC Facility

• Six Aseptic Clean Rooms 

• 21 CFR 211 Compliant

•NDA Enabling & Commercialization Scale Up









RadioMedix and Orano Med receive FDA Breakthrough Therapy Designation for AlphaMedixTM
RadioMedix and Orano Med receive FDA Breakthrough Therapy Designation for AlphaMedixTM in gastroenteropancreatic neuroendocrine tumors First Targeted Alpha Therapy to receive...
RadioMedix Inc. Acquisition of its 225Ac-PSMA I&T, a Targeted Alpha Therapy (TAT) for Metastatic Castration Resistant Prostate Cancer
RadioMedix Inc. Announces the Acquisition of its 225Ac-PSMA I&T program, a Targeted Alpha Therapy (TAT) for Metastatic Castration Resistant Prostate...
RadioMedix and Vect-Horus announce first dosing of GBM and Pancreatic ductal adenocarcinoma patients with 68Ga-RMX-VH
Houston, TX, USA and Marseille, France, Nov. 15, 2022  RadioMedix and Vect-Horus are pleased to announce that they have successfully...

JOIN US VIRTUALLY 

00Days
00Hours
00Minutes
00Seconds